Frontiers in New Drug Discovery : From Molecular Targets to Preclinical Trials

doi:10.3390/books978-3-0365-7682-4

Download Url(s)

https://mdpi.com/books/pdfview/book/7304

Contributor(s)

Aminin, Dmitry (editor)

Language

English

Show full item record

Abstract

The intention of this Special Issue is to focus on new aspects of drug discovery, including the search for new molecular targets of various diseases, the creation of new modern methods for diagnosing diseases, the development of new test systems and kits for assessing the selectivity and effectiveness of new drugs, the study of the molecular mechanisms of biologically active compounds, the formulation of new drugs, pharmacokinetic and pharmacodynamic studies, and preclinical trials of important molecules.

URI

https://directory.doabooks.org/handle/20.500.12854/100841

Keywords

Streptococci; antimicrobials; QSAR; MD simulation; Kunitz-type peptides; neuroprotective activity; sea anemones; TRPV1; P2X7R; Parkinson’s disease (PD); diffuse large B cell lymphoma (DLBCL); deep neural network; drug discovery; drug combination; biomarker; cancer severity; cancer prognosis; MAFB; tumor-associated macrophages; prostate cancer; photodynamic therapy; magnetic resonance imaging; ex vivo; anti-inflammatory substance; N-acylhydrazone; naphthyl-N-acylhydrazone; LASSBio-1524 analogues; phosphacoumarin; azomethine ylide; cycloaddition; anti-cancer; cytotoxicity; quantum chemistry; pravastatin; metformin; radiation-induced intestinal injury; minipigs; epithelial regeneration; inflammation; arylazo sulfones; DNA binding; DNA cleavage; DNA photocleavage; A375 melanoma cells; molecular docking; radicals; N–S bond homolysis; platinum(II); five-coordinate complexes; glycoconjugation; cytotoxic activity; protein X-ray structure; lipophilicity; natural products; acetylcholinesterase inhibitors; butyrylcholinesterase inhibitors; Alzheimer’s disease; central nervous system; n/a